The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
p53 Upregulates Death Receptor 4 Expression through an Intronic p53 Binding Site
Abstract
Death receptor 4 (DR4) is one of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors and triggers apoptosis on ligation with TRAIL or overexpression. Our previous study demonstrated that DR4 expression could be regulated in a p53-dependent fashion. In the present study, we have demonstrated that DR4 is a p53 target gene and is regulated by p53 through a functional intronic p53 binding site (p53BS) based on the following lines of evidence: (a) the p53BS in the DR4 gene is almost identical to the one found in the first intron of the DR5 gene in terms of their locations and sequences; (b) DR4 p53BS bound to p53 protein in intact cells upon p53 activation as demonstrated by a chromatin immunoprecipitation assay; (c) a luciferase reporter vector carrying the DR4 p53BS upstream of an SV40 promoter exhibited enhanced luciferase activity when transiently cotransfected with a wild-type p53 expression vector in p53-null cell lines or stimulated with DNA-damaging agents in a cell line having wild-type p53; and (d) when the DR4 p53BS, together with its own corresponding promoter region in the same orientation as it sits in its natural genomic locus, was cloned into a basic luciferase vector without a promoter element, its transcriptional activity was strikingly increased by cotransfection of a wild-type p53 expression vector or treatment with DNA-damaging agents. However, wild-type p53 or DNA-damaging agents completely lost their activity to increase transcriptional activity of a reporter construct with deleted DR4 p53BS. Thus, we conclude that p53 directly regulates the expression of the DR4 gene via the novel intronic p53BS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TNF receptors include the p53-induced targets FAS47, 48, 49 and TNFRSF10A–D;38, 39 these can be activated by external stimuli such as binding with FASL or TNF-α, thereby leading to caspase-dependent apoptosis.178”
From Census and evaluation of p53 target genes (2017) · cites this paper as [39]
Citations
Cites
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866
Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Decision making by p53: life, death and cancer
Oren, M. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401183 · Cited by 1,085
KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene
Wu, G. S., Burns, T. F., McDonald, E. R., Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-141 · Cited by 1,081
Molecular determinants of response to TRAIL in killing of normal and cancer cells.
Kim, K., Fisher, M. J., Xu, S., & El‐Deiry, W. S. (2000) · PubMed · Cited by 376
Takimoto, R., & El-Deiry, W. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203489 · Cited by 360
Identification of Modulators of TRAIL-Induced Apoptosis via RNAi-Based Phenotypic Screening
Aza‐Blanc, P., Cooper, C. L., Wagner, K., Batalov, S., Deveraux, Q. L., & Cooke, M. P. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00348-4 · Cited by 342
Cited by
Sorted by citations
Mitochondrial membrane permeabilization in cell death
Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
Overview of cell death signaling pathways
Jin, Z., & El‐Deiry, W. S. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.2.1508 · Cited by 1,345
Census and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
RAR and RXR modulation in cancer and metabolic disease
Altucci, L., Leibowitz, M. D., Ogilvie, K. M., de Lera, A. R., & Gronemeyer, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2397 · Cited by 517
Apoptosis: a mechanism of acute and chronic liver injury
Guicciardi, M. E., & Gores, G. J. (2005) · Gut · doi:10.1136/gut.2004.053850 · Cited by 514
The transcriptional targets of p53 in apoptosis control
Yu, J., & Zhang, L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.189 · Cited by 427
Henson, E. S., & Gibson, S. B. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.05.015 · Cited by 302
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam, D., Szegezdi, É., Keane, M., de Jong, S., & Samali, A. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.006 · Cited by 271
Death Receptor Regulation and Celecoxib-Induced Apoptosis in Human Lung Cancer Cells
Liu, X., Yue, P., Zhou, Z., Khuri, F. R., & Sun, S. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh322 · Cited by 266
Self-citationTAp63α induces apoptosis by activating signaling via death receptors and mitochondria
Gressner, O., Schilling, T., Lorenz, K., Schulze Schleithoff, E., Koch, A., Schulze‐Bergkamen, H., Maria Lena, A., Candi, E., Terrinoni, A., Valeria Catani, M., et al. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600708 · Cited by 255
Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
Stegh, A. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.643299 · Cited by 198
Death receptors as targets in cancer
Micheau, O., Shirley, S., & Dufour, F. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12238 · Cited by 189
Yodkeeree, S., Sung, B., Limtrakul, P., & Aggarwal, B. B. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1161 · Cited by 181
TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies
Holoch, P. A., & Griffith, T. S. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.06.066 · Cited by 181
Chemoresistance in solid tumours
Wilson, T. R., Longley, D. B., & Johnston, P. G. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl280 · Cited by 176
Müller, M., Schilling, T., Sayan, E., Kairat, A., Lorenz, K., Schulze‐Bergkamen, H., Oren, M., Koch, A., Tannapfel, A., Stremmel, W., et al. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401774 · Cited by 178
van Geelen, C. M. M., de Vries, E. G. E., & de Jong, S. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.11.002 · Cited by 167
The transcription factor p53: Not a repressor, solely an activator.
Fischer, M., Steiner, L., & Engeland, K. (2014) · Cell Cycle · doi:10.4161/15384101.2014.949083 · Cited by 153
Shankar, S., Ganapathy, S., Chen, Q., & Srivastava, R. K. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-16 · Cited by 157
Regulation of endothelial nitric oxide synthase by small RNA
Zhang, M., Ou, H., Shen, Y. H., Wang, J., Wang, J., Coselli, J. S., & Wang, X. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503853102 · Cited by 153
Dumont, P., Ingrassia, L., Rouzeau, S., Ribaucour, F., Thomas, S., Roland, I. H., Darro, F., Lefranc, F., & Robert Kiss, A. (2007) · Neoplasia · doi:10.1593/neo.07535 · Cited by 151
Rational bases for the development of EGFR inhibitors for cancer treatment
Bianco, R., Gelardi, T., Damiano, V., Ciardiello, F., & Tortora, G. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.05.008 · Cited by 144
Targeting apoptotic pathways for cancer therapy
Tian, X., Srinivasan, P. R., Tajiknia, V., Uruchurtu, A. F. S. S., Seyhan, A. A., Carneiro, B. A., Cruz, A. D. L., Pinho-Schwermann, M. P., George, A., Zhao, S., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179570 · Cited by 155
Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability
Ho, K. C., Zhou, Z., She, Y., Chun, A., Cyr, T. D., & Yang, X. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101273108 · Cited by 134
Ganapathy, S., Chen, Q., Singh, K. P., Shankar, S., & Srivastava, R. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015627 · Cited by 133
Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance
Zingoni, A., Fionda, C., Borrelli, C., Cippitelli, M., Santoni, A., & Soriani, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01194 · Cited by 126
Li, T., Su, L., Lei, Y., Liu, X., Zhang, Y., & Liu, X. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.645333 · Cited by 123
Self-citationChen, M., Wang, X., Zha, D., Cai, F., Zhang, W., He, Y., Huang, Q., Zhuang, H., & Hua, Z. (2016) · Scientific Reports · doi:10.1038/srep35468 · Cited by 126
Zhou, J., Lu, G., Ong, C.-S., Ong, C. N., & Shen, H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0071 · Cited by 116
Proteasome Inhibitor PS-341 (Bortezomib) Induces Calpain-dependent IκBα Degradation
Li, C., Chen, S., Yue, P., Deng, X., Lonial, S., Khuri, F. R., & Sun, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.072694 · Cited by 99
Self-citationRHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53
Sohr, S., & Engeland, K. (2008) · Cell Cycle · doi:10.4161/cc.7.21.7014 · Cited by 103
Regulation of Programmed Cell Death by the P53 Pathway
Kuribayashi, K., & El‐Deiry, W. S. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-6554-5_10 · Cited by 95
Carlisi, D., D’Anneo, A., Angileri, L., Lauricella, M., Emanuele, S., Santulli, A., Vento, R., & Tesoriere, G. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22494 · Cited by 93
Sullivan, K. D., Gallant‐Behm, C. L., Henry, R. E., Fraikin, J.-L., & Espinosa, J. M. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.01.004 · Cited by 96
Decoy Receptor 2 ( DcR2 ) Is a p53 Target Gene and Regulates Chemosensitivity
Liu, X., Yue, P., Khuri, F. R., & Sun, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0939 · Cited by 95
Self-citationMolecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum
Ali, A., Farrand, L., Kim, J. Y., Byun, S., Suh, J., Lee, H. J., & Tsang, B. K. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06734.x · Cited by 90
Delineating Crosstalk Mechanisms of the Ubiquitin Proteasome System That Regulate Apoptosis
Gupta, I., Singh, K., Varshney, N. K., & Khan, S. M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00011 · Cited by 88
TRAIL combinations: The new ‘trail’ for cancer therapy (Review)
Refaat, A., Abdrabou, A., & Reda, A. M. (2014) · Oncology Letters · doi:10.3892/ol.2014.1922 · Cited by 87
Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System
Abbas, R., & Larisch, S. (2021) · Cells · doi:10.3390/cells10123465 · Cited by 91
van Geelen, C. M. M., Westra, J. L., de Vries, E. G. E., Ek, W. B., Zwart, N., Hollema, H., Boezen, H. M., Mulder, N. H., Plukker, J. T. M., de Jong, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8809 · Cited by 71
Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells
Zhao, J., Lü, Y., & Shen, H. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.040 · Cited by 72
Chen, J., Chou, C., Chang, Y.-F., & Chen, C. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.12.8030 · Cited by 68
At a Crossroads to Cancer: How p53-Induced Cell Fate Decisions Secure Genome Integrity
Rizzotto, D., Englmaier, L., & Villunger, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910883 · Cited by 69
Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells
Surget, S., Chiron, D., Gomez‐Bougie, P., Descamps, G., Ménoret, E., Bataille, R., Moreau, P., Gouill, S. L., Amiot, M., & Pellat‐Deceunynck, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0487 · Cited by 64
Targeting death receptors for TRAIL by agents designed by Mother Nature
Prasad, S., Kim, J. H., Gupta, S. C., & Aggarwal, B. B. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.07.004 · Cited by 61
Hougardy, B. M. T., Maduro, J. H., van der Zee, A. G. J., de Groot, D. J. A., van den Heuvel, F. A. J., de Vries, E. G. E., & de Jong, S. (2005) · International Journal of Cancer · doi:10.1002/ijc.21580 · Cited by 61
Tomasetti, M., Anděra, L., Alleva, R., Borghi, B., Neužil, J., & Procopio, A. D. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.02.054 · Cited by 57
Kim, S. M., Woo, J. S., Jeong, C. H., Ryu, C. H., Lim, J. Y., & Jeun, S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0123 · Cited by 55
Akram, K. M., Lomas, N. J., Forsyth, N. R., & Spiteri, M. A. (2014) · Europe PMC (PubMed Central) · Cited by 53
Yoshida, T., Zhang, Y., Rosado, L. A. R., & Zhang, B. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0244 · Cited by 52
Park, J.-S., Oh, Y., Park, Y. J., Park, O., Yang, H. S., Slania, S., Hummers, L. K., Shah, A. A., An, H.-T., Jang, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09101-4 · Cited by 51
Resistance to TRAIL and how to surmount it
Maksimović‐Ivanić, D., Stošić‐Grujičić, S., Nicoletti, F., & Mijatović, S. (2012) · Immunologic Research · doi:10.1007/s12026-012-8284-8 · Cited by 51
Chen, S., Liu, X., Yue, P., Schönthal, A. H., Khuri, F. R., & Sun, S. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.037465 · Cited by 50
Self-citationDuiker, E. W., de Vries, E. G. E., Mahalingam, D., Meersma, G. J., Ek, W. B., Hollema, H., Hooge, M. N. L., van Dam, G. M., Cool, R. H., Quax, W. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1535 · Cited by 50
Lin, Y., Chen, S., Yue, P., Zou, W., Benbrook, D. M., Liu, S., Le, T. C., Berlin, K. D., Khuri, F. R., & Sun, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6209 · Cited by 50
Self-citationCorazza, N., Kassahn, D., Jakob, S., Badmann, A., & Brunner, T. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04905.x · Cited by 48
Britschgi, C., Rizzi, M., Grob, T. J., Tschan, M. P., Hügli, B., Reddy, V. A., Andres, A. ‐., Torbett, B. E., Tobler, A., & Fey, M. F. (2005) · Oncogene · doi:10.1038/sj.onc.1209240 · Cited by 50
Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL
Aguilera, D. G., Das, C. M., Sinnappah-Kang, N. D., Joyce, C., Taylor, P. H., Wen, S., Hasselblatt, M., Paulus, W., Fuller, G. N., Wolff, J. E. A., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9788-x · Cited by 50
Hu, H., Chai, Y., Wang, L., Zhang, J., Lee, H., Kim, S., & Lü, J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0288 · Cited by 49
Mendoza, F. J., Ishdorj, G., Hu, X., & Gibson, S. B. (2008) · APOPTOSIS · doi:10.1007/s10495-008-0210-0 · Cited by 47
Combined modality therapy with TRAIL or agonistic death receptor antibodies
Amm, H. M., Oliver, P. G., Lee, C. H., Li, Y., & Buchsbaum, D. J. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.5.14671 · Cited by 47
Han, N., Zhou, Q., Huang, Q., & Liu, K. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.084 · Cited by 45
The impact of post-transcriptional regulation in the p53 network
Freeman, J. A., & Espinosa, J. M. (2012) · Briefings in Functional Genomics · doi:10.1093/bfgp/els058 · Cited by 46
Sasaki, H., Ohara, N., Xu, Q., Wang, J., DeManno, D. A., Chwalisż, K., Yoshida, S., & Maruo, T. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0898 · Cited by 44
Wang, X., Huang, G., Mei, S., Qian, J., Ji, J., & Zhang, J. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.060 · Cited by 42
He, K., Jang, S., Joshi, J. P., Yoo, M.-H., & Ye, K. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-11-0923 · Cited by 47
Hu, L., Wang, Y., Chen, Z., Fu, L.-S., Wang, S., Zhang, X., Zhang, P., Lu, X., Jie, H.-Y., Li, M., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9675450 · Cited by 41
Shankar, E., Sivaprasad, U., & Basu, A. (2008) · Oncogene · doi:10.1038/onc.2008.39 · Cited by 41
Tan, S., Hougardy, B. M. T., Meersma, G. J., Schaap, B., de Vries, E. G. E., van der Zee, A. G. J., & de Jong, S. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076539 · Cited by 39
Zhang, T., Wang, X., He, D., Jin, X., & Guo, P. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000116 · Cited by 39
Pal, R., Srivastava, N., Chopra, R., Gochhait, S., Gupta, P., Prakash, N., Agarwal, G., & Bamezai, R. N. K. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-303 · Cited by 40
Critical role of Bid and Bax in indirubin-3′-monoxime-induced apoptosis in human cancer cells
Shi, J., & Shen, H. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.01.021 · Cited by 38
A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX
Henry, R. E., Andrysík, Z., París, R., Galbraith, M. D., & Espinosa, J. M. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.498 · Cited by 40
Ishdorj, G., Graham, B. A., Hu, X., Chen, J., Johnston, J. B., Fang, X., & Gibson, S. B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710177200 · Cited by 37
Kong, Q., Lv, J., Yan, S., Chang, K., & Wang, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102975 · Cited by 39
Zhuang, H., Jiang, W., Zhang, X., Qiu, F., Gan, Z., Cheng, W., Zhang, J., Guan, S., Tang, B., Huang, Q., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0947-3 · Cited by 37
Juglanin inhibits lung cancer by regulation of apoptosis, ROS and autophagy induction
Chen, L., Xiong, Y., Xu, J., Wang, J., Meng, Z., & Hong, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.21317 · Cited by 34
Zhang, S., Chen, Z., Shi, P., Fan, S., He, Y., Wang, Q., Li, Y., Ramalingam, S. S., Owonikoko, T. K., & Sun, S. (2021) · Theranostics · doi:10.7150/thno.54824 · Cited by 33
Self-citationNicolaou, K. A., Liapis, V., Evdokiou, A., Constantinou, C., Magiatis, P., Skaltsounis, A., Koumas, L., Costeas, P., & Constantinou, A. I. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.053 · Cited by 33
Inoue, T., Shiraki, K., Fuke, H., Yamanaka, Y., Miyashita, K., Yamaguchi, Y., Yamamoto, N., Ito, K., Sugimoto, K., & Nakano, T. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200603000-00004 · Cited by 33
Chemopreventive agent-induced modulation of death receptors
Sun, S. (2005) · APOPTOSIS · doi:10.1007/s10495-005-2274-4 · Cited by 33
Self-citationOh, Y., Jeon, Y.-J., Hong, G.-S., Kim, I., Woo, H., & Jung, Y.-K. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2011.209 · Cited by 31
Salinomycin inhibits epigenetic modulator EZH2 to enhance death receptors in colon cancer stem cells
Singh, A. K., Verma, A., Singh, A., Arya, R. K., Maheshwari, S., Chaturvedi, P., Nengroo, M. A., Saini, K. K., Vishwakarma, A. L., Singh, K., et al. (2020) · Epigenetics · doi:10.1080/15592294.2020.1789270 · Cited by 29
Yao, W., Oh, Y.-T., Deng, J., Yue, P., Deng, L., Huang, H., Zhou, W., & Sun, S. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.738302 · Cited by 29
Self-citationEGFR-targeting agents in oncology
Garofalo, S., Rosa, R., Bianco, R., & Tortora, G. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.8.889 · Cited by 29
Hamasu, T., Inanami, O., Asanuma, T., & Kuwabara, M. (2005) · Journal of Radiation Research · doi:10.1269/jrr.46.103 · Cited by 29
Raj, M. H., Yashaswini, B. K., Rössler, J. K., & Salimath, B. P. (2016) · APOPTOSIS · doi:10.1007/s10495-016-1223-8 · Cited by 28
Antitumor Activity of Bortezomib Alone and in Combination with Trail in Human Acute Myeloid Leukemia
Conticello, C., Adamo, L., Vicari, L., Giuffrida, R., Iannolo, G., Anastasi, G., Caruso, L. A., Moschetti, G., Cupri, A., Palumbo, G. A., et al. (2008) · Acta Haematologica · doi:10.1159/000151511 · Cited by 28
5-Fluorouracil-induced RNA stress engages a TRAIL-DISC-dependent apoptosis axis facilitated by p53
Akpinar, B., Bracht, E. V., Reijnders, D., Šafaříková, B., Jelínková, I., Grandien, A., Vaculová, A. H., Zhivotovsky, B., & Olsson, M. (2015) · Oncotarget · doi:10.18632/oncotarget.6030 · Cited by 26
Pal, R., Gochhait, S., Chattopadhyay, S., Gupta, P., Prakash, N., Agarwal, G., Chaturvedi, A., Husain, N., Husain, S. A., & Bamezai, R. N. K. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0900-5 · Cited by 28
Maduro, J. H., de Vries, E. G. E., Meersma, G.-J., Hougardy, B. M. T., van der Zee, A. G. J., & de Jong, S. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.06.1902 · Cited by 29
Hori, T., Kondo, T., Kanamori, M., Tabuchi, Y., Ogawa, R., Zhao, Q., Ahmed, K., Yasuda, T., Seki, S., Suzuki, K., et al. (2009) · Journal of Orthopaedic Research® · doi:10.1002/jor.21056 · Cited by 26
Qi, S., Kou, X., Lv, J., Qi, Z., & Yan, L. (2015) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2015.09.015 · Cited by 26
Artemisinin Derivatives Stimulate DR5-Specific TRAIL-Induced Apoptosis by Regulating Wildtype P53
Zhou, X., Zijlstra, S. N., Soto-Gamez, A., Setroikromo, R., & Quax, W. J. (2020) · Cancers · doi:10.3390/cancers12092514 · Cited by 24
Tahir, S. K., Calvo, E., Carneiro, B. A., Yuda, J., Shreenivas, A. V., Jongen‐Lavrencic, M., Gort, E. H., Ishizawa, K., Morillo, D., Biesdorf, C., et al. (2023) · Blood · doi:10.1182/blood.2022017333 · Cited by 26
A Study of TRAIL Receptors in Squamous Cell Carcinoma of the Head and Neck
Teng, M. S., Brandwein‐Gensler, M. S., Teixeira, M. S., Martignetti, J. A., & Duffey, D. C. (2005) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.131.5.407 · Cited by 24
Yang, Y., Wang, X., Zhang, Y., & Yuan, W. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.02.006 · Cited by 23
Targeting Trail Towards the Clinic
Mahalingam, D., Oldenhuis, C. N. A. M., Szegezdi, É., Giles, F. J., de Vries, E. G. E., de Jong, S., & Nawrocki, S. T. (2011) · Current Drug Targets · doi:10.2174/138945011798829357 · Cited by 23
Role of IG20 Splice Variants in TRAIL Resistance
Prabhakar, B. S., Mulherkar, N., & Prasad, K. V. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0493 · Cited by 23
Metadata
- Authors
- Liu, X., Yue, P., Khuri, F. R., & Sun, S.-Y.
- Affiliations
- Emory University (US)
- Venue
- Cancer Research
- Published
- 2004-08-01
- Volume
- 64
- Issue
- 15
- Pages
- 5078-5083
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2127891491
- Cited by
- 184
- References
- 29
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 5 · 2023: 8 · 2022: 2 · 2021: 3 · 2020: 7 · 2019: 6 · 2018: 7 · 2017: 7 · 2016: 7 · 2015: 5 · 2014: 11 · 2013: 5 · 2012: 17
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p53, death receptor 4, DR4, TRAIL receptors, DR5, transcriptional activation, DNA-damaging agents, apoptosis
- MeSH terms
- Binding Sites, Breast Neoplasms, Chromatin, DNA, DNA Damage, Female, Humans, Introns, Luciferases, Precipitin Tests, Promoter Regions, Genetic, Transcription, Genetic, Transfection, Tumor Cells, Cultured, Transcriptional Activation, Up-Regulation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Receptors, Tumor Necrosis Factor, Receptors, TNF-Related Apoptosis-Inducing Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review